Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of MUSIC: macitentan in idiopathic pulmonary fibrosis
2010-024211-13Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of macitentan in idiopathic pulmonary fibrosis (IPF), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: AEs leading to premature discontinuation of study drug. Started Apr 2011; status: completed.
02
Drugs
macitentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2010-024211-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024211-13.